Currently, there are 51.93M common shares owned by the public and among those 42.79M shares have been available to trade.
The company’s stock has a 5-day price change of 0.28% and 56.04% over the past three months. GTHX shares are trading 132.79% year to date (YTD), with the 12-month market performance up to 290.11% higher. It has a 12-month low price of $1.08 and touched a high of $7.12 over the same period. GTHX has an average intraday trading volume of 1.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 31.91%, 84.94%, and 104.12% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of G1 Therapeutics Inc (NASDAQ: GTHX) shares accounts for 38.42% of the company’s 51.93M shares outstanding.
It has a market capitalization of $371.19M and a beta (3y monthly) value of 1.64. The earnings-per-share (ttm) stands at -$0.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.31% over the week and 5.44% over the month.
Earnings per share for the fiscal year are expected to increase by 56.74%, and 126.31% over the next financial year.
Looking at the support for the GTHX, a number of firms have released research notes about the stock. JP Morgan stated their Neutral rating for the stock in a research note on January 30, 2023, with the firm’s price target at $7-$10. Needham coverage for the G1 Therapeutics Inc (GTHX) stock in a research note released on January 03, 2023 offered a Buy rating with a price target of $31. JP Morgan was of a view on November 04, 2021 that the stock is Underweight, while BTIG Research gave the stock Buy rating on October 15, 2021, issuing a price target of $51. JP Morgan on their part issued Neutral rating on September 30, 2021.
